Sanara MedTech (NASDAQ:SMTI – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.01, Zacks reports. The firm had revenue of $26.31 million during the quarter, compared to the consensus estimate of $22.75 million. Sanara MedTech had a negative return on equity of 19.86% and a negative net margin of 10.71%.
Sanara MedTech Stock Down 5.0 %
Shares of NASDAQ SMTI opened at $29.63 on Thursday. The company has a quick ratio of 2.02, a current ratio of 2.23 and a debt-to-equity ratio of 0.76. The firm has a 50-day moving average price of $34.34 and a 200 day moving average price of $33.79. Sanara MedTech has a 52 week low of $26.00 and a 52 week high of $39.08. The stock has a market capitalization of $259.00 million, a price-to-earnings ratio of -29.93 and a beta of 1.37.
Analysts Set New Price Targets
A number of equities analysts recently weighed in on the stock. HC Wainwright lifted their price objective on shares of Sanara MedTech from $50.00 to $51.00 and gave the company a “buy” rating in a research report on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $46.00 price objective on shares of Sanara MedTech in a report on Wednesday.
About Sanara MedTech
Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.
Recommended Stories
- Five stocks we like better than Sanara MedTech
- Overbought Stocks Explained: Should You Trade Them?
- Carnival Corporation Will Cruise to Higher Price Points This Year
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- Energy Transfer: Powering Data With Dividends and Diversification
- The Basics of Support and Resistance
- Qualcomm Stock Is Coiling for a Breakout
Receive News & Ratings for Sanara MedTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanara MedTech and related companies with MarketBeat.com's FREE daily email newsletter.
